Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VIR Vir Biotechnology, Inc.

Not Yet Opened 12-10 16:00:00 EST

6.55

-0.11

-1.65%

盘后6.68

+0.13+1.98%

18:42 EST

High6.89	Low6.49	Vol1.78M
Open6.69	D1 Closing6.66	Amplitude5.99%
Mkt Cap911.27M	Tradable Cap619.33M	Total Shares139.13M
T/O11.79M	T/O Rate1.88%	Tradable Shares94.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":6.55,"timestamp":1765400400000,"preClose":6.66,"halted":0,"volume":1778392,"hourTrading":{"tag":"盘后","latestPrice":6.68,"preClose":6.55,"latestTime":"18:42 EST","volume":33149,"amount":217188.09,"timestamp":1765410121977},"delay":0,"floatShares":94554590,"shares":139125032,"eps":-3.622804,"marketStatus":"Not Yet Opened","change":-0.11,"latestTime":"12-10 16:00:00 EST","open":6.69,"high":6.89,"low":6.4913,"amount":11793111.8684456,"amplitude":0.059865,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.622804,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765443600000},"marketStatusCode":0,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":6.66,"preHourTrading":{"tag":"盘前","latestPrice":6.7051,"preClose":6.66,"latestTime":"09:13 EST","volume":68,"amount":455.5240168,"timestamp":1765375987630},"postHourTrading":{"tag":"盘后","latestPrice":6.68,"preClose":6.55,"latestTime":"18:42 EST","volume":33149,"amount":217188.09,"timestamp":1765410121977},"volumeRatio":0.792467,"impliedVol":0.6645,"impliedVolPercentile":0.4},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"2589332882","title":"Vir Biotechnology Insiders Sold US$1.1m Of Shares Suggesting Hesitancy","url":"https://stock-news.laohu8.com/highlight/detail?id=2589332882","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589332882?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:32","pubTimestamp":1765189975,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders may have reason to be concerned, as several insiders sold their...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-insiders-sold-us11m-of-shares-suggesting-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/vir-biotechnology-insiders-sold-us11m-of-shares-suggesting-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","VIR","BK4585","BK4568","BK4535"],"gpt_icon":0},{"id":"2588060158","title":"Director Vicki L. Sato Reports Sale of Vir Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588060158","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588060158?lang=en_us&edition=fundamental","pubTime":"2025-12-03 08:48","pubTimestamp":1764722917,"startTime":"0","endTime":"0","summary":"Vicki L. Sato, Director at Vir Biotechnology Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL759zP9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Vicki L. Sato Reports Sale of Vir Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","BK4585","BK4568","VIR"],"gpt_icon":0},{"id":"2588031447","title":"SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588031447","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588031447?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:30","pubTimestamp":1764624642,"startTime":"0","endTime":"0","summary":"SVF Endurance  Ltd has reported a disposal of common shares of Vir Biotechnology Inc. According to the filing, other reporting beneficial owners include SOFTBANK VISION FUND  L.P. and SB INVESTMENT ADVISERS  LTD. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL3S9st7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4535","VIR","BK4139","BK4585"],"gpt_icon":0},{"id":"1187950486","title":"Vaccine Stocks Falls as FDA Vows to Impose New Vaccine Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=1187950486","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187950486?lang=en_us&edition=fundamental","pubTime":"2025-12-01 23:25","pubTimestamp":1764602721,"startTime":"0","endTime":"0","summary":"Moderna Inc. fell Monday after the Food and Drug Administration said in a memo late last week it would place new restrictions on which vaccines hit the market.Vinay Prasad, a top FDA official, blamed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"de4e5ce05b2acd5962228944615f4d01","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BNTX","REGN","MRK","NVAX","PCVX","AMGN","AZN","BIIB","VIR","HIMS","MRNA"],"gpt_icon":0},{"id":"2586298319","title":"SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586298319","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586298319?lang=en_us&edition=fundamental","pubTime":"2025-11-27 05:31","pubTimestamp":1764192704,"startTime":"0","endTime":"0","summary":"SVF Endurance  Ltd reported a disposal of common shares of Vir Biotechnology Inc., according to a recent SEC Form 4 filing. Other reporting beneficial owners include SoftBank Vision Fund  L.P. and SB Investment Advisers  Ltd, among other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL9s0jkP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"SVF Endurance (Cayman) Ltd Reports Disposal of Vir Biotechnology Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","VIR","BK4568","BK4139","BK4535"],"gpt_icon":0},{"id":"2585870140","title":"H.C. Wainwright Keeps Their Buy Rating on Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2585870140","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585870140?lang=en_us&edition=fundamental","pubTime":"2025-11-22 01:35","pubTimestamp":1763746531,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology yesterday and set a price target of $15.00. According to TipR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-vir-biotechnology-vir-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-vir-biotechnology-vir-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR"],"gpt_icon":0},{"id":"2584975547","title":"Vir Biotechnology CEO to Join Evercore Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2584975547","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584975547?lang=en_us&edition=fundamental","pubTime":"2025-11-20 05:05","pubTimestamp":1763586352,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. announced that Chief Executive Officer Marianne De Backer will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3 in Miami, Florida. A live webcast of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on November 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nNDL5tkKGM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR","BK4568","BK4585","BK4127","BK4139","BK4535","EVR"],"gpt_icon":0},{"id":"2582861349","title":"Barclays Sticks to Their Buy Rating for Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582861349","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582861349?lang=en_us&edition=fundamental","pubTime":"2025-11-12 13:35","pubTimestamp":1762925728,"startTime":"0","endTime":"0","summary":"Barclays analyst Gena Wang maintained a Buy rating on Vir Biotechnology yesterday and set a price target of $31.00. The company’s shares closed yes...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-vir-biotechnology-vir-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-their-buy-rating-for-vir-biotechnology-vir-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR"],"gpt_icon":0},{"id":"1127241931","title":"Stock Track | Vir Biotechnology (VIR) Soars 5.03% as Analysts Maintain Buy Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1127241931","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127241931?lang=en_us&edition=fundamental","pubTime":"2025-11-12 03:20","pubTimestamp":1762888830,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. (VIR) shares are soaring 5.03% in intraday trading on Tuesday, buoyed by positive analyst ratings from major financial institutions. The biotechnology company's stock is...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VIR"],"gpt_icon":0},{"id":"1190163920","title":"Stock Track | Vir Biotechnology (VIR) Soars 5.03% on Bullish Analyst Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1190163920","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190163920?lang=en_us&edition=fundamental","pubTime":"2025-11-12 03:20","pubTimestamp":1762888830,"startTime":"0","endTime":"0","summary":"Shares of Vir Biotechnology, Inc. (VIR) are surging in intraday trading, with the stock price soaring 5.03%. This significant uptick comes on the heels of bullish analyst ratings from two major...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VIR"],"gpt_icon":0},{"id":"2582366676","title":"Morgan Stanley Sticks to Its Buy Rating for Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366676","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366676?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:18","pubTimestamp":1762863502,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Vir Biotechnology, with a price target of $20.00. The co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-buy-rating-for-vir-biotechnology-vir-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-its-buy-rating-for-vir-biotechnology-vir-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VIR"],"gpt_icon":0},{"id":"2582362351","title":"Vir Biotechnology (VIR) Gets a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2582362351","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582362351?lang=en_us&edition=fundamental","pubTime":"2025-11-11 16:58","pubTimestamp":1762851524,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau maintained a Buy rating on Vir Biotechnology yesterday. The company’s shares closed yesterday at $5.37. According to T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vir-biotechnology-vir-gets-a-buy-from-td-cowen-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vir-biotechnology-vir-gets-a-buy-from-td-cowen-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4207","BK4568","BK4535","TD","VIR","COWN","BK4139","BK4566","BK4127"],"gpt_icon":0},{"id":"2582877099","title":"Some Analysts Just Cut Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582877099","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582877099?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:58","pubTimestamp":1762779482,"startTime":"0","endTime":"0","summary":"The analysts covering Vir Biotechnology, Inc. ( NASDAQ:VIR ) delivered a dose of negativity to shareholders today, by...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/some-analysts-just-cut-their-vir-biotechnology-inc-nasdaqvir","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vir/vir-biotechnology/news/some-analysts-just-cut-their-vir-biotechnology-inc-nasdaqvir","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4535",".IXIC","VIR","TSYW.SI","MNQmain","SQQQ","PSQ","QID","QLD","TQQQ","USJW.SI","NVIW.SI","BK4139","BK4568","USAW.SI","BK4585","NQmain"],"gpt_icon":1},{"id":"1122127674","title":"Stock Track | Vir Biotechnology Surges 11.11% Pre-market on Promising Hepatitis Delta Treatment Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1122127674","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122127674?lang=en_us&edition=fundamental","pubTime":"2025-11-10 17:52","pubTimestamp":1762768343,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. (VIR) saw its stock soar 11.11% in pre-market trading on Monday, following the announcement of positive Phase 2 results for its combination therapy targeting chronic hepatitis...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VIR"],"gpt_icon":0},{"id":"1184089781","title":"Stock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1184089781","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184089781?lang=en_us&edition=fundamental","pubTime":"2025-11-10 09:26","pubTimestamp":1762737987,"startTime":"0","endTime":"0","summary":"Shares of Vir Biotechnology, Inc. (VIR) surged 8.38% in a 24-hour period, following the announcement of positive Phase 2 results for its chronic hepatitis delta (CHD) treatment. The biotechnology...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VIR"],"gpt_icon":0},{"id":"1108352609","title":"Stock Track | Vir Biotechnology Soars 8.38% on Positive Phase 2 Results for Hepatitis Delta Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1108352609","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108352609?lang=en_us&edition=fundamental","pubTime":"2025-11-10 09:26","pubTimestamp":1762737978,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc. (VIR) saw its stock surge 8.38% in a 24-hour period, following the announcement of positive Phase 2 results for its combination therapy targeting chronic hepatitis delta...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VIR"],"gpt_icon":0},{"id":"2582814633","title":"Vir Biotechnology announces Week 48 endpoint analysis of Phase 2 SOLSTICE","url":"https://stock-news.laohu8.com/highlight/detail?id=2582814633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582814633?lang=en_us&edition=fundamental","pubTime":"2025-11-10 08:20","pubTimestamp":1762734015,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta, CHD, demons...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-announces-week-48-endpoint-analysis-of-phase-2-solstice-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-announces-week-48-endpoint-analysis-of-phase-2-solstice-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","VIR","BK4568","BK4535"],"gpt_icon":0},{"id":"2582581952","title":"Vir Biotechnology Reports Positive Phase 2 Results for Tobevibart and Elebsiran in Hepatitis Delta","url":"https://stock-news.laohu8.com/highlight/detail?id=2582581952","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582581952?lang=en_us&edition=fundamental","pubTime":"2025-11-10 07:10","pubTimestamp":1762729801,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. announced results from its Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta . Data presented at The Liver Meeting of the American Association for the Study of Liver Diseases  and published in the New England Journal of Medicine showed that 66% of participants receiving a monthly dose of the combination achieved undetectable hepatitis delta virus  RNA at Week 48. The combination was well-tolerated, with no grade 3 or higher treatment-related adverse events and no treatment-related discontinuations reported. The ECLIPSE registrational program for the combination therapy is underway, with topline data expected in the first quarter of 2027. The combination has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, as well as Priority Medicines and orphan drug designations from the European Medicines Agency.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251109:nNDL6LFr4f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","BK4585","VIR","BK4568"],"gpt_icon":0},{"id":"2581839857","title":"Vanina de Verneuil, EVP and General Counsel, Reports Sale of Vir Biotechnology Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581839857","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581839857?lang=en_us&edition=fundamental","pubTime":"2025-11-08 04:28","pubTimestamp":1762547314,"startTime":"0","endTime":"0","summary":"Vanina de Verneuil, EVP, General Counsel, and Corporate Secretary of Vir Biotechnology Inc., reported a disposal of common shares of Vir Biotechnology Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDLbMk39d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vanina de Verneuil, EVP and General Counsel, Reports Sale of Vir Biotechnology Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4585","BK4535","VIR"],"gpt_icon":0},{"id":"2581988651","title":"Vir Biotechnology to Present at Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2581988651","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581988651?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:01","pubTimestamp":1762524064,"startTime":"0","endTime":"0","summary":"Vir Biotechnology Inc. will participate in the Jefferies 2025 London Healthcare Conference on November 18, 2025. Chief Executive Officer Marianne De Backer is scheduled to present at the event. A live webcast of the presentation will be available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire  on November 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL6vFL6N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4535","VIR","BK4585","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":0.1829},{"period":"1month","weight":0.2982},{"period":"3month","weight":0.2982},{"period":"6month","weight":0.2759},{"period":"1year","weight":-0.2362},{"period":"ytd","weight":-0.0926}],"compareEarnings":[{"period":"1week","weight":0.0022},{"period":"1month","weight":0.018},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.1313},{"period":"1year","weight":0.1296},{"period":"ytd","weight":0.1654}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.477739},{"month":2,"riseRate":0.333333,"avgChangeRate":0.037395},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.121524},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.08783},{"month":5,"riseRate":0.666667,"avgChangeRate":0.058008},{"month":6,"riseRate":0.5,"avgChangeRate":0.020036},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.044477},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.0277},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.115495},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03118},{"month":11,"riseRate":0.857143,"avgChangeRate":0.105555},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.044039}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}